SGLT2 inhibitors reduce hospitalization for heart failure in patients with or without diabetes through mechanisms including ion-exchange regulation, volume regulation, and ventricular remodeling.
What are the mechanisms of action and clinical value of SGLT2 inhibitors in the treatment of heart failure?
This review summarizes the clinical value and underlying mechanisms of SGLT2 inhibitors in treating heart failure, highlighting their role beyond diabetes management.
ABSTRACT: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to treat diabetes mellitus. Abundant evidence has shown that SGLT2 inhibitors can reduce hospitalization for heart failure (HF) in patients with or without diabetes. An increasing number of studies are being conducted on the mechanisms of action of SGLT2 inhibitors in HF. Our review summarizes a series of clinical trials on the cardioprotective effects of SGLT2 inhibitors in the treatment of HF. We have summarized several classical SGLT2 inhibitors in cardioprotection research, including empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and sotagliflozin. In addition, we provided a brief overview of the safety and benefits of SGLT2 inhibitors. Finally, we focused on the mechanisms of SGLT2 inhibitors in the treatment of HF, including ion-exchange regulation, volume regulation, ventricular remodeling, and cardiac energy metabolism. Exploring the mechanisms of SGLT2 inhibitors has provided insight into repurposing these diabetic drugs for the treatment of HF.
Xie et al. (Sun,) conducted a review in Heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors reduce hospitalization for heart failure in patients with or without diabetes through mechanisms including ion-exchange regulation, volume regulation, and ventricular remodeling.